Imagine destroying a liver tumour with a needle, no incision, no scar. That's tumor ablation — using heat (radiofrequency, microwave) or cold (cryoablation) to kill cancer cells. The tumor ablation market report by MRFR shows that radiofrequency (RF) ablation is the largest technology, but microwave is the fastest‑growing. The market is $1.5 billion and will hit $5.13 billion by 2035, growing at 11.82% CAGR. Why the explosion? Because patients want less invasive options, and outcomes are excellent.

What's driving growth? Surgical ablation is the largest treatment type, but percutaneous ablation is the fastest‑growing — done through a small needle, often under CT or ultrasound guidance. The tumor ablation market analysis highlights that liver cancer is the largest application, but lung cancer is the fastest‑growing — as screening detects more early‑stage nodules.

What's new? Irreversible electroporation (IRE) — a non‑thermal ablation that preserves blood vessels and bile ducts. Also, robotic‑assisted ablation for precision.

The bottom line: if you have a small tumour (liver, lung, kidney), ask about ablation. It's not for everyone, but for the right patient, it's a game‑changer.